Lychee seed extract protects against neuronal injury and improves cognitive function in rats with type II diabetes mellitus with cognitive impairment

YONG TANG¹,²*, CHONGLIN YU³*, JIANMING WU¹, HAIXIA CHEN¹, YUAN ZENG¹, XIULING WANG¹, LE YANG⁴, QIBING MEI¹, SHOUSONG CAO⁵ and DALIAN QIN¹

¹Laboratory of Chinese Materia Medica, Department of Pharmacology, School of Pharmacy;  
²Pharmacy Intravenous Admixture Services, Affiliated Hospital of Traditional Chinese Medicine;  
³Department of Human Anatomy, School of Preclinical Medicine, Southwest Medical University, Luzhou, Sichuan 646000;  
⁴Chengdu Analytical Applications Center, Shimadzu (China) Co., Ltd., Chengdu, Sichuan 610063;  
⁵Laboratory of Cancer Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan 646000, P.R. China

Received December 25, 2016; Accepted October 19, 2017

DOI: 10.3892/ijmm.2017.3245

Abstract. Lychee seed is a traditional Chinese medicine and has many beneficial effects such as modulation of blood sugar and lipids, antioxidation, antivirus and antitumor. Studies have indicated that type II diabetes mellitus (T2DM) and Alzheimer’s disease (AD) share common biological mechanisms including insulin resistance, impaired glucose metabolism, β-amyloid (Aβ) formation, oxidative stress and presence of advanced glycation end products (AGEs). The present study investigated the effects of lychee seed extract (LSE) on neuroprotection, cognitive function improvement and possible underlying mechanisms in a rat model of T2DM with cognitive impairment. We analyzed the chemical profile of LSE using a UHPLC-SPD chromatogram and evaluated its effect on the improvement of spatial learning and memory of rats by a Morris water maze. The levels of glucose, insulin, Aβ, AGEs, Tau protein and acetylcholinesterase in the blood and/or hippocampus of rats were determined by blood-glucose meter, radioimmunoassay, chemical chromatometry, enzyme-linked immunosorbent assay (ELISA) and immunohistochemical analysis, respectively. Results demonstrated that LSE consists of eight major and around 20 minor ingredients, and it remarkably prevents neuronal injury and improves cognitive functions in T2DM rats. The levels of glucose, insulin, Aβ, AGEs, and Tau protein were significantly increased in the blood and/or hippocampus of T2DM rats, while LSE remarkably decreased their levels compared to vehicle treatment (P<0.01). The possible mechanisms may be associated with IR improvement and decreased formations of Aβ, AGEs and Tau protein in the hippocampus of T2DM rats. LSE may be developed as the agent for the treatment of T2DM and/or AD clinically.

Introduction

Lychee (Litchi in Chinese) is an edible fruit of the Sapindaceae family in China and Southeast Asia and it is botanically designated as Litchi chinensis Sonn (1,2). Lychee seed is the dry mature seed of a lychee and used as a traditional Chinese medicine named ‘Li-zhi-he’ in Chinese and was recorded by the Bencao Yanyi (Development of Herbal Medicine) and Bencao Gangmu (Compendium of Materia Medica) for regulating Qi, dispelling cold, alleviating pain and relieving polydipsia (3). Modern pharmacological studies have identified that some components of lychee seed have the effects of modulation...
of blood sugar by improving insulin resistance (IR) (4,5), lowering blood lipids (6), antioxidation (7), antivirus (8), anti-tumor (9) and preventing liver injury (10).

Type II diabetes mellitus (T2DM) is one of the most common chronic diseases in the world (11). T2DM is a metabolic disorder characterized by hyperglycemia and its development is due to pancreatic βcells failing to secrete sufficient amounts of insulin to meet metabolic demand (12,13). T2DM causes various serious complications of heart, eyes, nerves, liver and kidneys and is associated with decrements in cognitive function and changes in brain structure (14). IR in pancreatic β cells contributes to the pathogenesis of T2DM (13).

Alzheimer’s disease (AD) is the major causative disease of dementia and it is characterized pathologically by the accumulation of senile plaques (SPs) and neurofibrillary tangles (NFTs) in the brain (15). Emerging evidence suggests that T2DM can contribute significantly to the onset and/or progression of AD either directly or as a cofactor (16). Numerous studies have evidenced that T2DM is a major risk factor in the pathology of AD, and that the two diseases share common biological mechanisms at the molecular level including IR, impaired glucose metabolism, β‑amyloid (Aβ) formation, oxidative stress and presence of advanced glycation end products (AGEs) (16‑19). IR is likely to be the basis for a variety of pathological changes in AD, and improvement of IR can delay the onset and progression of AD (20,21).

Currently, the drugs for AD treatment can only improve patients’ cognition, however they do not slow the progression or cure the disease (22). Development of drugs for the treatment of AD have a very high failure rate due to lack of therapeutic efficacy or emergence of serious adverse effects; no new drug has been approved for AD treatment since 2003 (23). Therefore, discovery and development of novel anti-AD drugs is urgently needed. Previously, active ingredients from natural products and medicinal herbs for treatment of AD and/or diabetes mellitus have attracted substantial attention. Studies have shown that some natural products have neuroprotective effects (24,25). The aqueous extract from lychee seed improved the ability of learning and memory in mice (26). The saponins isolated and extracted from lychee seeds significantly relieved cognitive dysfunction by improving IR in rats. In the present study, we analyzed the chemical profile of lychee seed extract (LSE) by ultrahigh performance liquid chromatography (UHPLC)-SPD. In order to study the effects of LSE on neuroprotection and cognitive function improvement, we also established a rat model of T2DM with cognitive impairment and investigated the ability of spatial learning and memory in rats by Morris water maze. In addition, the effects of LSE on neuropathology of the neurons were studied by pathohistological analysis. Furthermore, to explore the possible mechanisms associated with the effects of LSE on neuroprotection and cognitive function improvement, the levels of glucose, insulin, Aβ, acetylcholinesterase (AChE), AGEs, and Tau protein in blood and/or hippocampus were determined by blood-glucose meter, radioimmunoassay, chemical chromatometry, enzyme-linked immunosorbent assay (ELISA) and immunohistochemical analysis, respectively.

Materials and methods

Reagents. Donepezil hydrochloride tablets (Aricept, cat. no. H20070181) were purchased from Eisai China Inc. (Chengdu, China), and prepared to a mixed suspension at the concentration of 0.1 mg/ml as a positive control. Streptozotocin (STZ; cat. no. S0130) was purchased from Sigma‑Aldrich; Merck KGaA (Darmstadt, Germany). Aβ release analysis kit (cat. no. 200805) and serum insulin radioimmunoassay kit (cat. no. 200808) were purchased from the Chinese PLA General Hospital (Beijing, China). Tau protein assay kit (cat. no. BM3928) was purchased from Wuhan Boster Biological Technology, Ltd. (Hubei, China). AChE assay kit (cat. no. A024) was purchased from Nanjing Jiancheng Bioengineering Institute (Jiangsu, China). AGEs assay kit (cat. no. CEB353Ge) was purchased from Wuhan USCN Business Co., Ltd. (Hubei, China). Morris water maze system (MT-2000) was purchased from Chengdu Techman Software Co., Ltd. (Sichuan, China).

Experimental animals. A total of 150 8‑10‑week old (body weight, 180‑220 g) specific pathogen free grade male Sprague Dawley rats were purchased from the Experimental Animal Centre, Sichuan Provincial Academy of Medical Sciences (Chengdu, China; SCXK 201302). All rats were housed in sterile plastic cages (up to 4 rats per cage) with free access to water and food ad libitum in a controlled room temperature (22±1°C), humidity (50‑70%) and under a 12‑h light/dark cycle. All animal experiments were performed strictly in accordance with institutional guidelines and followed an approved protocol (permit no. 250114) by the Committee on Use and Care of Animals of Southwest Medical University (Sichuan, China). There were 10‑12 rats for each experimental group.

Collection, extraction and isolation of lychee seeds. Lychee seeds were purchased from a local market in Luzhou, China, and were authenticated by Professor Can Tang of School of Pharmacy, Southwest Medical University (Luzhou, China). A total mass of 1,000 g of air-dried lychee seeds were ground and soaked with 1,000 ml of 70% ethanol overnight, extracted by percolation with 8,000 ml of 70% ethanol at the speed of 5 ml/min/kg. Following this, the solvents were evaporated under vacuum, then the LSE was concentrated to dryness using a rotary vacuum evaporator and collected to yield a total mass of 185.2 g dried powder.

Analysis of chemical profile of LSE. The chemical profile of LSE was performed at 254 nm by an LCMS‑8040 UHPLC system (Shimadzu Corp., Kyoto, Japan). Chromatographic analyses were performed at 45°C with an Inert Sustain C18 column (2.0 mm particle size, 50x2.1 mm; GL Sciences, Tokyo, Japan), using water: Formic acid (100:0.1, v/v) and methanol as the mobile phase A and B, respectively. The mobile phase was delivered at a rate of 0.25 ml/min with injection volume of 1 μl. The gradient separation process was as follows: 15‑15% B at 0‑2.0 min, 15‑80% B at 2.0‑5.0 min, 80‑80% B at 5.0‑7.0 min, 80‑15% B at 7.0‑7.5 min. The data were analyzed by LabSolutions software version 5.75 (Shimadzu Corp.).

Morris water maze test. The spatial learning and memory ability was investigated using the Morris water maze test as
described previously (28,29). Briefly, the test was conducted in a round white pool (94 cm in diameter and 31 cm deep) filled with water (30 cm depth) with the temperature ~25°C. The escape platform was a 25 cm² Plexiglas square, placed in the center of one quadrant of the pool, 15 cm from the pool's edge and submerged 1 cm beneath the water surface.

Hidden platform test: Each rat was trained in a circular pool, which randomly divided into four equal quadrants by a hidden platform with four trials for 120 sec per trial daily with 30 min intervals between the trials for 5 consecutive days. The time for the rat to seek the platform was record by an online image video tracking system and within 120 sec as the escape latency.

Spatial probe test: The platform was removed from the pool after the hidden platform test, each rat was left to one quadrant of the pool which was farthest from the primary platform. The number of rats crossing the platform, the time spent in the target quadrant and the percentage of time spent in the target quadrant were recorded by a tracking system.

Establishment of the rat model of T2DM with cognitive impairment. Rats were selected by Morris water maze test as the standard of 40-120 sec to find the platform, the rat was eliminated if it found the platform in <40 sec or more than 120 sec, as described previously (29,30). The selected rats were randomly divided into control group (n=12) and study group (n=100). The rats in the control group were fed with normal standard diet, while the rats in the study group were fed with high fat, high sugar and high protein diet (HFSP, food ratio: carbohydrate 25%, protein 15.2%, fat (lard) 58.8%, and sodium cholate 1% (31,32). The body weights of rats were weighed every two weeks. Then, the rats were then continuously fed the HFSP diet and weighed weekly for 4 more weeks. Finally, the rats were further examined if it found the platform in <40 sec or more than 120 sec, as described previously (28,29). Briefly, the test was conducted.

Drug preparation and administration. The T2DM rats with cognitive impairment were randomly divided into five groups with 10 rats for each group and treated with normal saline (NS) 1 ml/kg (negative control), LSE 0.7, 1.4 and 2.8 g/kg by intragastric (IG) administration once a day (daily) at 8 a.m. for 28 consecutive days. In addition, 10 normal rats on a normal diet were given equal volume of NS as additional control. The dose of donepezil was selected as previous described from literature (33).

Measurement of blood glucose. The blood samples of rats were collected from the tail veins, and blood glucose was measured by blood-glucose meter, as described previously (34). HOMA was calculated for IR index and the method of calculation is described above.

Determination of the levels of glucose, insulin, AChE, Aβ and AGEs in the blood and/or hippocampus of rats. A total of 10 rats for each group were randomly selected after Morris water maze test, then weighed and anesthetized with 1% pentobarbital sodium (0.4 ml/kg) by IP injection. Bloods were taken from the abdominal aorta for detection of the levels of insulin, AChE and Aβ. The tissues of brain were collected. The freshly dissected hippocampal tissues were isolated to prepare hippocampal tissue homogenates for detection of the contents of AChE, Aβ and AGEs. Insulin, AChE, Aβ and AGEs were measured by serum insulin radioimmunoassay kit, AChE assay kit, Aβ release analysis kit and AGEs assay kit, respectively.

Determination of the expression of Tau protein in hippocampal neurons of rats by immunohistochemical analysis. The expression of Tau protein in the hippocampus of rats was carried out with immunohistochemical staining and examined under microscope, as previous described (33). The positive rate of the expression of Tau protein was calculated by GD-10.0 image analysis system. A total of 10 rats were used for each group.

Histopathological examination of hippocampus neuron CAI pyramidal cells of rats with hematoxylin and eosin (H&E) staining. The rats were anesthetized by IP injection of 1.0% pentobarbital and perfusion with 4% paraformaldehyde to fix the brains for 24 h after treatment. Then, the brains of rats were removed and the brain tissues were weighed, fixed in 10% neutral buffered formalin, dehydrated and embedded in paraffin for coronal microtome sections (~4-5 µm) with H&E staining for the study, as described previously (35). The sections were observed for pathohistological changes under light microscope.

Statistical analysis. All the data were presented as mean ± standard deviation (SD). Statistical differences of the data among the means of two or more groups were analyzed by Student's t-test and/or one-way univariate analysis of variance (ANOVA). A value of P<0.05 was considered to indicate a statistically significant difference, and a value of P<0.01 was considered to indicate a highly statistically significant difference.

Results

The chemical profile of LSE. To determine the chemical profile of LSE isolated and extracted from lychee seed, we studied its chemical fingerprint at 254 nm by a UHPLC-SPD chromatogram and the data are presented in Fig. 1. The data display the main chemical compositions of LSE and indicate that it mainly consists of eight major (Fig. 1) and around 20 minor ingredients.

Establishment of a rat model of T2DM with cognitive impairment. To establish the rat model of T2DM with cognitive impairment, the rats were initially fed with HFSP diet for 8 weeks and observed the general condition including food and water intakes, hair color, activities and body weight changes and compared to those of the rats with normal standard diet (control). These was no difference in general condition between the two groups, however, the body weights of the
rats with HFSP diet were significantly increased (P<0.01) compared to those of control rats (Fig. 2A). Then, the rats were injected with a single dose of STZ (27 mg/kg, IP x1) after 8 weeks on the HFSP diet. Interestingly, the food and water intakes, as well as urine volumes were gradually increased, while the body weights of the rats were decreased (P<0.01) following injection with STZ compared to the normal control rats (Fig. 2B), indicating the rats displayed the symptoms of T2DM.

Next, the blood glucose and insulin levels were measured and HMOA was calculated in the T2DM rats and compared to those of the normal rats (control); the results are illustrated in Fig. 3. The data show that there were no significant differences of blood glucose (Fig. 3A), insulin (Fig. 3B) and HMOA (Fig. 3C) between the rats on the HFSP diet and the rats on regular standard diet (P>0.05) in the 8 weeks before STZ injection as 6.33±3.01 vs. 6.57±3.21 mmol/l, 8.57±3.18 vs. 9.14±2.66 µIU/l, and 2.1±0.43 vs. 2.67±0.38, respectively. However, the blood glucose, insulin and HMOA were increased significantly (P<0.01) following STZ injection in the rats on the HFSP diet compared to those of the rats on regular standard diet without STZ treatment, as 3.62-fold (22.93±3.74 vs. 6.34±2.81 mmol/l), 4.95-fold (44.23±5.21 vs. 8.94±2.95 µIU/l), and 17.89-fold (45.08±0.87 vs. 2.52±0.37) increases, respectively. These data indicated that the rat model of T2DM was successfully established (Fig. 3A-C).

Finally, we evaluated the cognitive function of T2DM rats by a navigation test starting 1 h after STZ treatment during the first 5 days to see whether the cognition was impaired or not compared to the normal rats (control) and the results...
are presented in Fig. 3D. The escape latency of T2DM rats was slightly increased but no statistically significant differences were observed in the first and the second days after SZT treatment. However, the escape latency of T2DM rats was significantly higher than that of the normal rats on the days 3-5 (P<0.01). In the last navigation test (on day 5), the escape latency was 22.35±5.12 sec (Fig. 3A) for normal rats and 59.42±5.32 sec (Fig. 3B) for T2DM rats, respectively. Therefore, the number was 62.39% by the calculation formula of (B-A)/B%, suggesting that T2DM rats have obvious cognitive impairment according to the judgment standard of dementia criteria of (B-A)/B% >20% (36).

Effects of LSE on the cognitive function of the T2DM rats with cognitive impairment. Following successfully establishing the rat model of T2DM with cognitive impairment, the effects of LSE on cognitive functions of the T2DM rats were investigated using Morris water maze test, a commonly used method for assessing cognitive functions, and compared to that of NS (as negative control) and donepezil (as positive control) treatments, as well as the normal rats treated with NS. The results are illustrated in Fig. 4. First, the Hidden platform test was performed in the normal rats and T2DM rats on the day 1-5 after STZ treatment to investigate the ability of learning and memory. As presented in Fig. 4A, the escape latency time of the T2DM rats was significantly increased compared to that of the normal rats (P<0.01). However, LSE at the doses of 0.7, 1.4 and 2.8 g/kg/day and donepezil at 0.42 mg/kg/day by intragastric administration for 28 consecutive days significantly shortened the escape latency compared to NS treatment (P<0.01) in the T2DM rats (Fig. 4A).

Next, the spatial probe test was performed for the rats. Similarly, the residence time (Fig. 4B), the numbers of crossing platform (Fig. 4C), and the percentage of time spent in the target quadrant (Fig. 4D) were significantly shortened in the T2DM rats (P<0.01) compared to those of the normal rats. LSE (0.7, 1.4 and 2.8 g/kg/day x28 days) significantly increased the residence time (Fig. 4B), the numbers of those crossing the platform (Fig. 4C), and the the percentage of time spent in the target quadrant (Fig. 4D) compared to NS treatment (P<0.01) in the T2DM rats. In addition, donepezil (0.42 mg/kg/day x28 days) has similarly effect on the spatial learning and memory of the T2DM rats as LSE at the dose of 2.8 g/kg/day.

The detailed classical path of the latency to get to the platform for the normal rats treated with NS and the T2DM rats treated with NS, donepezil or LSE during the acquisition trials are shown in Fig. 5. The data indicate that LSE and donepezil can improve the ability of spatial learning and memory of the T2DM rats (Figs. 4 and 5).

Effects of LSE on the blood glucose, insulin and HMOA in T2DM rats. The development of T2DM is due to pancreatic β cells failed to secrete sufficient insulin to meet metabolic demand to cause hyperglycemia (12). T2DM and AD share common biological mechanisms, including IR and impaired glucose metabolism (16). Therefore, we examined the effects of LSE on blood glucose, insulin and HMOA in the T2DM rats, and the results are shown in Fig. 6. The blood glucose (Fig. 6A), insulin (Fig. 6B) and HMOA (Fig. 6C) levels of the T2DM rats were significantly higher than those of

Figure 3. Effects of HFSP diet alone and in combination with STZ on (A) serum glucose (white bars, control rats; black bars, T2DM rats), (B) insulin (white bars, control rats; black bars, T2DM rats), (C) HOMA (white bars, control rats; black bars, T2DM rats) and (D) escape latency of the normal (control, ○ and T2DM, ◼) rats. The rats were fed with HFSP diet for 8 weeks, then injected a single dose of STZ (27 mg/kg, intraperitoneal injection) and fed the HFSP diet for another 4 weeks. There were 10 rats used for each experimental group. The results are presented as mean ± standard deviation. *P<0.01 vs. STZ group; ^P<0.01 vs. before HFSP diet. HFSP, high fat, high sugar and high protein; STZ, streptozocin; HOMA, homeostasis model assessment.
the normal rats (P<0.01) as 24.35±3.30 vs. 6.34±0.72 mmol/l, 42.42±4.88 vs. 8.94±2.95 µIU/l and 45.90±0.72 vs. 2.52±0.37, respectively. There are 3.84‑, 4.74‑fold and 18‑, 21‑fold increases in blood glucose, insulin and HMOA in the T2DM rats compared to normal rats, respectively.

However, LSE at the doses of 0.7, 1.4 and 2.8 g/kg/day significantly decreased the blood glucose (14.74±1.50, 13.19±2.57 and 12.33±2.46 mmol/l), insulin (23.09±6.54, 20.04±4.93 and 16.09±3.00 µIU/l), and HMOA (15.13±0.44, 11.75±0.56 and 8.82±0.33) in a dose-dependent manner compared to NS treatment in the T2DM rats (P<0.01), although the reductions did not reach the same level in normal rats. Interestingly, donepezil (4.2 mg/kg/day) also significantly decreased the blood glucose (15.60±1.77 µIU/l) and HMOA (25.09±0.31) in the hippocampus of T2DM rats compared to that of normal rats. However, LSE at the doses of 0.7, 1.4 and 2.8 g/kg/day significantly decreased the concentrations of AChE in the blood (9.19±0.90, 8.57±1.00 and 7.51±0.75 µmol/ml, respectively), while increased the concentrations of AChE in the hippocampus (1.10±0.43 and 1.22±0.40 U/mg, respectively) compared to NS treatment in the T2DM rats (P<0.01). The AChE inhibitor donepezil also significantly decreased the concentrations of AChE in the blood (5.94±1.04 µmol/ml) and increased the concentrations of AChE in the hippocampus (1.77±0.47 U/mg).

The AChE inhibitors such as donepezil reduce the rate of acetylcholine degradation to increase its concentration in the brain to execute their anti-AD effect. Therefore, we evaluated the concentrations of AChE in the blood and in the hippocampus of T2DM rats and compared to that of the normal rats (Fig. 7A and B). Interestingly, the concentrations of AChE were significantly increased in the blood (14.08±1.55 vs. 5.34±0.99 µmol/ml) but markedly decreased in the hippocampus (0.51±0.14 vs. 2.66±0.37 U/mg) compared to normal control rats. However, LSE at the doses of 0.7, 1.4 and 2.8 g/kg/day significantly increased the concentrations of AChE in the blood (9.19±0.90, 8.57±1.00 and 7.51±0.75 µmol/ml, respectively), while increased the concentrations of AChE in the hippocampus (1.10±0.43 and 1.22±0.40 U/mg, respectively) compared to normal control rats. However, LSE at the doses of 0.7, 1.4 and 2.8 g/kg/day significantly increased the concentrations of AChE in the blood (9.19±0.90, 8.57±1.00 and 7.51±0.75 µmol/ml, respectively), while increased the concentrations of AChE in the hippocampus (1.10±0.43 and 1.22±0.40 U/mg, respectively) compared to NS treatment in the T2DM rats (Fig. 7A and B). The AChE inhibitor donepezil also significantly decreased the concentrations of AChE in the blood (5.94±1.04 µmol/ml) and increased the concentrations of AChE in the hippocampus (1.77±0.47 U/mg).

One of the histopathological hallmarks of AD is deposition of Aβ plaques. Therefore, the effect of LSE on Aβ in the blood and hippocampus of T2DM rats was studied and compared to that of donepezil; the results are illustrated in Fig. 7C and D. The concentrations of Aβ are significantly increased (P<0.01) in the T2DM rats compared to normal rats, while LSE at the doses of 0.7, 1.4 and 2.8 g/kg/day significantly decreased the concentrations of Aβ in the blood (9.19±0.90, 8.57±1.00 and 7.51±0.75 µmol/ml, respectively), while increased the concentrations of Aβ in the hippocampus (1.10±0.43 and 1.22±0.40 U/mg, respectively) compared to normal control rats.
in the blood and in the hippocampus in T2DM rats compared to that of normal control rats (10.36±1.54 vs. 1.66±0.35 pg/ml in the blood and 0.65±0.03 vs. 0.12±0.03 mmol/mg in the hippocampus, respectively). Similarly, LSE at the doses of 0.7, 1.4 and 2.8 g/kg/day significantly decreased (P<0.01) the concentrations of Aβ in the blood (4.65±0.60, 3.73±0.45 and 2.54±0.59 pg/ml, respectively) and in the hippocampus (0.25±0.03, 0.22±0.02 and 0.19±0.03 mmol/mg, respectively) compared to NS treatment in T2DM rats (Fig. 7C and D). Donepezil also significantly decreased (P<0.01) the concentrations of Aβ in the blood (5.45±0.58 pg/ml, P<0.01) and in the hippocampus (0.51±0.04 mmol/mg, P<0.05) compared to NS treatment in T2DM rats (Fig. 7C and D). LSE, lychee seed extract; HFSP, high fat, high sugar and high protein; STZ, streptozotocin; NS, normal saline; IG, intragastric.

Effects of LSE on reductions of AGEs and Tau protein in the hippocampus of T2DM rats. AGEs have been implicated in diabetes related complications and serve an important role in the pathogenesis of AD. Therefore, we studied the effect of LSE on AGEs in the hippocampus of T2DM rats and the results are presented in Fig. 8. AGEs in the hippocampus of T2DM rats are much higher (P<0.01) compared to that of the normal rats (675.48±29.41 vs. 285.90±41.22 pg/ml). However, LSE (0.7, 1.4 and 2.8 g/kg/day) and donepezil (4.2 mg/kg/day) partially but significantly decreased (P<0.01) AGEs in the hippocampus of T2DM rats compared to NS treatment, the concentrations of AGEs were reduced to 524.19±20.92, 486.77±32.90, 456.94±20.06 and 488.29±33.87 pg/ml, respectively.

The intracellular accumulation of aggregated Tau protein is another histopathological hallmark of AD. Therefore, we investigated the effect of LSE on the expression of Tau protein in the hippocampus of T2DM rats with immunohistochemical staining under the microscope, and the representative
Figure 6. Effects of LSE on the (A) blood glucose, (B) insulin and (C) HOMA in T2DM rats. The normal rats were treated with NS (1 ml/kg/day, IG x28) and the T2DM rats induced by high fat, high sugar and high protein diet and STZ (27 mg/kg, intraperitoneal x1) were treated with NS (1 ml/kg/day, IG x28), Don (0.42 mg/kg/day, IG x28) or LSE (0.7, 1.4 and 2.8 g/kg/day, IG x28). There were 10 rats used for each experimental group and are expressed as the mean ± standard deviation. *P<0.05 vs. T2DM rats treated with NS; **P<0.01 vs. T2DM rats treated with NS; #P<0.01 vs. LSE 0.7 g/kg group. LSE, lychee seed extract; T2DM, type 2 diabetes mellitus; HOMA, homeostasis model assessment; NS, normal saline; STZ, streptozotocin; Don, donepezil; IG, intragastric.

Figure 7. Effects of LSE on AChE (A and B) and A β (C and D) in the blood and the hippocampus of T2DM rats. The normal rats were treated with NS (1 ml/kg/day), and T2DM rats induced by high fat, high sugar and high protein diet and (STZ, 27 mg/kg, intraperitoneal x1) were treated with NS (1 ml/kg/day), Don (0.42 mg/kg/day), or LSE (0.7, 1.4 and 2.8 g/kg/day, IG x28 days). There were 10 rats used for each experimental group and are expressed as the mean ± standard deviation. *P<0.05 vs. T2DM rats treated with NS; **P<0.01 vs. T2DM rats treated with NS; #P<0.01 vs. LSE 0.7 g/kg group. LSE, lychee seed extract; AChE, acetylcholinesterase; NS, normal saline; STZ, streptozotocin; Don, donepezil; IG, intragastric.
The neuronal cells of the hippocampus of T2DM rats and high dose of LSE (2.8 g/kg) effectively prevent the depositions of AGEs and Tau protein in T2DM rats by histopathological examination and the results are illustrated in Fig. 10. Interestingly, the morphology of the neuronal cells is nearly normal (LSE, 0.7 and 1.4 g/kg) or completely normal (LSE, 2.8 g/kg) after LSE treatments, the cells arrange more closely and orderly with increased cell numbers and normal shape, a large and round nucleus, and a clear nucleolus (Fig. 10D-F).

The results indicated that LSE effectively protects the hippocampal neuronal cells injury in a dose-dependent manner in T2DM rats, and is more effective than donepezil.

Discussion

T2DM and AD are very common diseases. The rapid increases of T2DM and AD incidences in the elderly population have been observed. Evidence has proven that there is a close link between T2DM and AD, and that the two diseases share common biological mechanisms at a molecular level. T2DM can significantly contribute to the onset and/or progression of AD, and T2DM patients are at higher risk of AD (38). The common pathology for both T2DM and AD is IR, impaired glucose metabolism, Aβ formation, oxidative stress and presence of AGEs. IR may be the pathological basis of the link between T2DM and AD (39,40). IR promotes AD pathological changes of Aβ deposition and Tau protein phosphorylation and induces sustained high blood glucose to accelerate the formation of AGEs (41-44). Studies have indicated that abnormal structural components such as amyloid precursor (APP), apolipoprotein E (ApoE), very low density lipoprotein (VLDL), AD, Aβ and Tau protein are all related to the pathological changes of AD in the brain tissues (43-45). Aβ and Tau protein are the molecular basis for the formation of SPs and NFTs. IR indirectly enhances the activity of glycogen synthase kinase-3β (GSK-3β) and promotes the AD-like Tau hyperphosphorylation in the hippocampus of the mice and rats in animal models of insulin dysfunction (46). In addition, IR can regulate the activity of γ-secretase enzyme by GSK-3β (47), promote the synthesis of Aβ and Aβ-42, inhibit the activity of insulin degrading enzyme and reduce the degradation of Aβ (48). Furthermore, insulin plays a pivotal role in regulation of energy metabolism, growth, survival and differentiation of neuronal cells via insulin signaling in the brain (49,50). Therefore, improving IR may be one of the important strategies for effective prevention and treatment of AD (51,52). Recent studies have demonstrated that improvement of IR may indeed delay the onset and/or progression of AD in the animals and patients (53,54). In the present studies, the blood glucose, insulin and HMOA are significantly increased in T2DM rats and LSE significantly decreases the elevated glucose, insulin and HMOA in a dose-dependent manner compared to NS treatment (P<0.01) in T2DM rats (Fig. 6). The data indicate that LSE can indeed improve IR in T2DM rats.
Currently, the drugs used for AD management can only improve cognition and behavior of AD patients, but cannot slow progression or cure the disease (22). In order to discover and develop more effective and less toxic novel anti-AD drugs, we established a rat model of T2DM with AD-like neurodegeneration and cognitive impairment by feeding the rats with HSFP diet for 8 weeks and then intraperitoneal injection of STZ (27 mg/kg) and continued HSFP diet for another 4 weeks. The rat model of T2DM was validated by high levels of blood glucose, insulin and HOMA as well as impaired
spatial learning and memory of the rats (Fig. 3). The model has the characteristics and pathogenesis of both T2DM and AD. It is reliable, reproducible and easy to be produced and shows high resemblance as the T2DM and/or AD in the aging patients. Therefore, it is an excellent model for study of cognitive impairment and drug screening of T2DM and/or AD.

Natural products and medicinal herbs are important sources for drug discovery against various diseases including AD and T2DM (55). The use of drug substances derived from natural sources has a long tradition in medicine (56). In the present study, we evaluated the effect of LSE, which was isolated and extracted from lychee seeds on the anti-diabetic and anti-AD efficacy, and compared to donepezil, the standard drug for AD treatment. The main components of LSE were determined and it was found that primarily consists of eight major ingredients and around 20 minor ingredients by a UHPLC-SPD chromatogram (Fig. 1). It has been reported that the chemical components of lychee seeds comprise volatile categories, saponins, flavonoids, organic, fatty, amino acids and sugar (7). The preliminary studies revealed that the saponins isolated and extracted from lychee seeds are the main effective ingredients for the anti-diabetic and anti-AD efficacy. In addition, it was demonstrated that LSE significantly improves cognitive function in T2DM rats with cognitive impairment for shortening the escape latency, increasing the number across the platform, platform quadrant dwell time and the percentage of time spent in the target quadrant compared to NS treatment (Figs. 4 and 5). Furthermore, LSE markedly alleviates neuronal injury in T2DM rats by morphological study (Fig. 10).

It has been reported that AD is associated with reduction of cholinergic activity of neurons (37). The dysfunction of cholinergic system is closely related to AD (21). Four of five FDA approved medications (donepezil, tacrine, rivastagmine
and galantamine) for AD management are AChE inhibitors by reducing the rate of acetylcholine degradation, and thereby increase its concentration in the brain. AChE in the blood and the hippocampus of T2DM rats were investigated and the concentrations of AChE were significantly increased in the blood but significantly decreased in the hippocampus compared to that of normal control rats (Fig. 7A and B). The authors are unsure as to how to explain why the concentrations of AChE in the hippocampus compared to NS were different in the blood and hippocampus in T2DM rats. Both LSE and donepezil significantly decreased the concentrations of AChE in the blood and increased the concentrations of AChE in the hippocampus compared to NS treatment (P<0.01) in T2DM rats (Fig. 7A and B).

Histopathological hallmarks of AD are deposition of Aβ plaques and formation of NFTs, which are primarily made up of aggregated Tau protein (57,58). The neurotoxic activities of Aβ include generation of reactive oxygen species (ROS), lipid peroxidation, calcium overload and eventually leading to neuronal death (59). The progressive accumulation of Tau protein leads to instability of the microtubular structure and results in loss of effective intracellular transport and neuronal death (60). AGEs also play an important role in the pathogenesis of both T2DM and AD. The present results showed that Aβ, Tau protein and AGEs in the hippocampus of T2DM rats were significantly increased compared to that of normal control rats (P<0.01). LSE can effectively prevent the depositions of Aβ, Tau protein and AGEs in the neuronal cells of hippocampus in T2DM rats and LSE is more effective than that of donepezil for reducing the formation of Aβ, Tau protein, and AGEs (Figs. 7D, 8 and 9). Therefore, LSE may be developed as the agent for the treatment of T2DM and/or AD. However, further studies are needed to find out and purify the active ingredient(s) from LSE and investigate the associated mechanistic action and molecular pathways of neuronal protection.

In conclusion, LSE mainly consists of eight major and around 20 minor ingredients, and significantly improves cognitive function such as the ability of spatial learning and memory and obviously protects from neuronal injury in T2DM rats with cognitive impairment through reducing blood glucose, improving IR and inhibiting the formation of Aβ, Tau protein and AGEs (Figs. 7D, 8 and 9). Therefore, LSE may be developed as the agent for the treatment of T2DM and/or AD clinically. However, further studies are required to find out the active contents of LSE and related long-term toxicity.

Acknowledgements

The present study was supported by grants from the Science and Technology Planning Project of Sichuan Province, China (grant nos. 2008SZ0050, 14JC0798 and LZ-LY-38), Science and Technology Program of Luzhou, Sichuan, China (grant nos. 14JC0056, 2015-S-43 and 2016LZXNYD-T03), Educational Commission of Sichuan Province, China (grant nos. 10ZA035, 15ZA0155 and 16ZA0187), Key Development Program of Southwest Medical University (grant nos. 2010ZD-010 and 2014QN-043) and the Distinguished Professor Research Startup Funding (S.C.) from Southwest Medical University (grant no. 2015-RCYJ0002). The authors would like to thank Professor Can Tang of the Department of Chinese Materia Medica, School of Pharmacy, Southwest Medical University (Luzhou, China) for authenticating the lychee seeds used in the studies.

References

1. Jiang YM, Yao L, Amon L and Li JR: Postharvest biology and technology of litchi fruit. J Food Agric Environ 1: 76-81, 2003.
2. Yang B, Wang J, Jiao M, Liu Y, Wang W and Jiang Y: Identification of polysaccharides from pericarp tissues of litchi (Litchi chinensis Somn.) fruit in relation to their antioxidant activities. Carbohydr Res 341: 634-638, 2006.
3. Kilari EK and Putta S: Biological and phytopharmacological descriptions of Litchi chinensis. Pharmacogn Rev 10: 60-65, 2016.
4. Xiao ZJ, Guo JW and Xu F: Effect of litchi saponin and litchi flavonoids on insulin resistance in HepG2 cells. J Pharm Prac 4: 316-318, 2015.
5. Ye HM, Zhong CY and Lv JH: Improving effect of litchi seed saponins on learning and memory impairment in mice. Acad J Guangzhou Med Univ 2: 10-14, 2015.
6. Jiang YM, Yuan H and Tian JX: Effects of saponin of litchi seed on gluconeogenesis and metabolism of blood lipid in mice. J Hangzhou Teach Coll 6: 435-436, 2005.
7. Zhang J and Zhang C: Research progress on the antineoplastic pharmacological effects and mechanisms of Litchi seeds. Chin Med 6: 20-26, 2015.
8. Li W, Zhu YT, Huang ZY, He JJ, Pei J and Song JP: Experimental studies on anti-fluvirus effect of litchi seed in vivo. Chin J Ethnomed Ethnopharm 18: 34-36, 2011.
9. Zhao M, Yang B, Wang J, Liu Y, Yu Lan and Jiang Y: Immunomodulatory and anticaner activities of flavonoids extracted from litchi (Litchi chinensis Somn.) pericarp. Int Immunopharmacol 7: 162-166, 2007.
10. Xiao LY, Pan QJ and Rao WN: The research of protective effect of litchi seed of experimental liver injury in mice. Chin J Tradit Chin Med Pharm 20: 42-43, 2005.
11. Whiting DR, Guariguata L, Weil C and Shaw J: IDF diabetes atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 94: 311-321, 2011.
12. Kasuga M: Insulin resistance and pancreatic beta cell failure. J Clin Invest 116: 1756-1760, 2006.
13. Spellman CW: Pathophysiology of type 2 diabetes: Targeting islet cell dysfunction. J Am Osteopath Assoc 110 (Suppl 2): S2-S7, 2010.
14. Mohcet A, Mangia S and Sequeist ER: Impact of diabetes on cognitive function and brain structure. Ann NY Acad Sci 1353: 60-71, 2015.
15. Kimura N: Diabetes mellitus induces Alzheimer's disease pathophysiology: Histopathological evidence from animal models. Int J Mol Sci 17: 503, 2016.
16. Mushitq G, Khan JA and Kamal MA: Biological mechanisms linking Alzheimer's disease and type-2 diabetes mellitus. CNS Neurolog Disord Drug Targets 13: 1192-1201, 2014.
17. Aliev G, Shahida K, Gan SH, Firoz C, Khan A, Abuzeinadah AM, Kamal W, Kamal MA, Tan Y, Xu Qu et al.: Alzheimer disease and type 2 diabetes mellitus: The link to tyrosine hydroxylase and probable nutritional strategies. CNS Neurolog Disord Drug Targets 13: 467-477, 2014.
18. Riederer P, Bartl J, Lau X and Grünblatt E: Diabetes type II: A risk factor for depression-Parkinson-Alzheimer? Neurotox Res 19: 253-265, 2011.
19. Yarchoo M and Arnold SE: Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease. Diabetes 63: 2553-2561, 2014.
20. Gasparini L, Netzer WJ, Greengard P and Xu H: Does insulin dysfunction play a role in Alzheimer's disease? Trends Pharmacol Sci 23: 288-293, 2002.
21. Mushitq G, Greig NH, Khan JA and Kamal MA: Status of acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease and type 2 diabetes mellitus. CNS Neurolog Disord Drug Targets 13: 1432-1439, 2014.
22. Lee JH, Jeong SK, Kim BC, Park KW and Dash A: Donepezil across the spectrum of Alzheimer's disease: Dose optimization and clinical relevance. Acta Neurol Scand 131: 259-267, 2015.
23. Gledhill J, Jończyk J, Panek D and Malawska B: Therapeutic strategies for Alzheimer's disease in clinical trials. Pharmacol Rep 68: 127-138, 2016.
31. Giacobini E and Gold G: Alzheimer disease therapy - moving from amyloid-β to tau. Nat Rev Neurol 9: 677-686, 2013.

32. Ashraf GM, Greig NH, Khan TA, Hassan I, Tabrez S, Shakil S, Sheiki IA, Zaidi SK, Akram M, Jaffer NR, et al: Protein misfolding and aggregation in Alzheimer's disease and type 2 diabetes mellitus. CNS Neurol Disord Drug Targets 13: 1280-1293, 2014.

33. Deutsch SI, Rosse RB and Lakshman RM: Dysregulation of tau phosphorylation is a hypothesized point of convergence in the pathogenesis of alzheimer's disease, frontotemporal dementia and schizophrenia with therapeutic implications. Prog Neuropsychopharmacol Biol Psychiatry 30: 1369-1380, 2006.

34. Soro-Paavonen A, Watson AM, Li J, Paavonen K, Koitka A, Calkin AC, Barit D, Coughlan MT, Drew BG, Lancaster GI, et al: Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes 57: 2461-2469, 2008.

35. Marszalek M: Diabetes type 2 and Alzheimer disease - one or two diseases? Mechanisms of association. Postepy Hig Med Dosw 67: 653-671, 2013 (In Polish).

36. El Khoury NB, Gratze M, Papon MA, Bretteville A and Panel E: Insulin dysfunction and Tau pathology. Front Cell Neurosci 8: 22, 2014.

37. Wang H, Wang R, Zhao Z, Ji Z, Xu S, Holščer C and Sheng S: Coexistence of insulin signaling-related proteins and choline acetyltransferase in neurons. Brain Res 1249: 237-243, 2009.

38. Kang JH, Korecka M, Toledo JR, Trojanowski JQ and Shaw LM: Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-β(1-42) and t proteins as Alzheimer disease biomarkers. Clin Chem 59: 903-916, 2013.

39. Bingham EM, Hopkins D, Smith D, Pernet A, Hallett W, Reed L, Marsden PK and Amiel SA: The role of insulin in human brain glucose metabolism: An 18fluoro-deoxyglucose positron emission tomography study. Diabetes 51: 3384-3390, 2002.

40. Li Y, Tsui W, Rusinek H, Butler T, Mosconi L, Pirraglia E, Mozley D, Vallabhajosula S, Harada R, Furumoto S, et al: Cortical laminar binding of PET amyloid and tau tracers in Alzheimer disease. J Nucl Med 56: 270-273, 2015.

41. Takalo M, Haapasalo A, Martiskainen H, Kurkinen KM, Kivisto H, Miettinen P, Khandelwal VK, Kempainen S, Kaminiska D, Mäkinen P, et al: High-fat diet increases tau expression in the brain of T2DM and AD mice independently of peripheral metabolic status. J Nutr Biochem 25: 634-641, 2014.

42. Hung AS, Liang Y, Chow TC, Tang HC, Wu SL, Wai MS and Yew DT: Mutated tau, amyloid and neuroinflammation in Alzheimer disease-A brief review. Prog Histochem Cytochem 50: 1-38, 2016.

43. Anékonda TS and Reddy PH: Can herbs provide a new generation of drugs for treating Alzheimer's disease? Brain Res Brain Res Rev 50: 361-376, 2005.

44. Farver D: The use of ‘natural products’ in clinical medicine. J D Med J 49: 129-130, 1996.

45. Blass JP, Ko L and Wisniewski HM: Pathology of Alzheimer's disease. Psychiatr Clin North Am 14: 397-420, 1991.

46. Iqbal K, Liu F, Gong CX and Grundke-Iqbal I: Tau in Alzheimer disease-A brief review. Prog Histochem Cytochem 50: 1-38, 2016.

47. Wei W, Wang X and Kusiak JW: Signaling events in amyloid beta-peptide-induced neuronal death and insulin-like growth factor I protection. J Biol Chem 277: 17649-17656, 2002.

48. Alonso AD, Grundke-Iqbal I, Barra HS and Iqbal K: Abnormal phosphorylation of tau and the mechanism of Alzheimer neurofibrillary degeneration: Sequestration of microtubule-associated proteins 1 and 2 and the disassembly of microtubules by the abnormal tau. Proc Natl Acad Sci USA 94: 298-303, 1997.